Forget short-term pain! Buy these FTSE 100 stars for long-term gain

Royston Wild looks at two brilliant FTSE 100 (INDEXFTSE: UKX) stocks for long-term investors.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Medical mammoth AstraZeneca (LSE: AZN) hasn’t yet managed to get over the enduring hump of patent expirations, despite the bright work being achieved by its development teams.

Exclusivity losses on revenue-driving labels like its Crestor cholesterol battler has seen the Cambridge business fail to punch any sort of earnings increase since 2011. And City analysts suggest that AstraZeneca’s troubles aren’t done yet, with declines of 6% and 3% expected for 2016 and 2017 respectively.

Investing in the pharmaceuticals sector is rarely plain sailing, the impact of product delays and even terminations resulting in potentially-explosive capex bills or bigger financial holes in the form of lost revenues. This — allied with AstraZeneca’s aforementioned patent problems — may make it a risk too far for cautious stock selectors.

But I believe braver investors can look forward to abundant returns in the years ahead as the firm’s product pipeline churns out the next generation of sales stars. And AstraZeneca is dedicating investment to white-hot growth areas like diabetes, an area where sales exploded 18% during January-June as demand for its relatively-new Farxiga product soared.

And AstraZeneca is also pulling up trees in emerging markets, a particularly exciting story as healthcare spend in these ‘new’ regions gathers pace. Revenues from such territories rose 7% in the first half, helped by rocketing demand for respiratory treatment Symbicort — sales of the product soared 33% in China alone during the period.

A forward P/E rating of 15.5 times nudges above the FTSE 100 average of 15 times, but I reckon AstraZeneca’s solid pipeline, allied with a chunky 4.2% dividend yield, makes it a bargain at the current time.

Phone in a fortune

BT Group’s (LSE: BT-A) potentially game-changing acquisition of mobile giant EE back in January is expected to produce a rare earnings blip in the current fiscal period.

Indeed, a 11% drop is expected by the Square Mile in the year to March 2017. But I reckon a subsequent prospective earnings multiple of 12.7 times represents terrific value given the rising might of BT’s multi-services proposition.

The company’s decision to throw its broadband customers free access to BT Sport proved a game-changer in breaking Sky’s dominance of the market.

Although BT no longer offers this deal, the huge sums ploughed into top-tier sporting events like UEFA Champions League and FA Premier League football, UFC cage fighting and Aviva Premiership rugby has made its sports channels a hit with couch potatoes all over the land.

Additionally, the London company’s aim to spread its internet network over the country is also paying off handsomely, giving it a 79% share of all net broadband additions during April-June. This helped push revenues at BT’s Consumer division 9% higher in the quarter, to £1.18bn.

Furthermore, BT’s ability to generate vast quantities of cash is expected to keep powering the dividend — a reward of 14p per share in fiscal 2016 is anticipated to rise to 15.5p in the current period, yielding a splendid 4.1%.

With the company’s acquisition of mobile giant EE providing BT’s sales outlook with a further shot in the arm, I reckon the company should prove a lucrative pick for patient investors.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and Sky. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »